is known for electronics not biotechnology, but that could change in future
years as Samsung Biologics has opened a new state of the art biologics
development and production facility in Incheon, Korea. To assure ongoing compliance with biologics
manufacturing quality standards, Samsung BioLogics chose
STARLIMS to be its LIMS provider.
“STARLIMS will provide Samsung its LIMS software to help
enhance functional support for quality assurance laboratory testing and for
storing and delivering analytical test results,” said Thomas Li, account
manager, STARLIMS Asia Pacific.
“STARLIMS passed a thorough audit and evaluation by Samsung Biologics,
which demonstrates our capability to support the business needs of a world
class customer operating a large contract product development and manufacturing
The new Incheon facility will
develop and manufacture a wide range of biologics products through genetic
engineering technologies, cell culturing and purification. By 2013, Samsung Biologics will offer a broad range of
mammalian cell based, cGMP manufacturing services for cell line development,
process and analytical development, clinical and commercial manufacturing, as
well as aseptic fill and finish operations.
“Our biologics facility is
capable of producing high quality bulk drug products. We are pleased that our quality control department is
relying on STARLIMS leading edge laboratory informatics solutions to help
guarantee that all process and final production are high quality, meet global
regulatory standards, and maximize customer satisfaction,” said Ming fang Hong,
quality control team leader, Samsung Biologics.